Topoisomerase II α - A fundamental prognostic factor in breast carcinoma

Polish Journal of Pathology

Volumn 60, Issue 2, 2009, Pages 67-75

  Hajduk, Magdalena ^a  

^a Diagnostic Centre 'PATOLOG'   (Poland)

Author keywords

Breast carcinoma; Topoisomerase II a

Indexed keywords

DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; ENZYME IMMUNOASSAY; ENZYMOLOGY; FEMALE; HUMAN; LYMPHADENECTOMY; MASTECTOMY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODE EXCISION; MASTECTOMY; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77952227479     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Bagwell CB, Clark GM, Spyratos F, et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry 2001; 46: 121-135.
2. Clark GM. Prognostic and predictive factors. In: Diseases of the Breast. Harris JR, Lippman ME, Morrow M, et al. (eds). Lippincott-Rayen Publishers, Philadelphia 1996; 461-485.
3. Hayes DF. Breast Cancer. In: Prognostic Factors in Cancer. Gospodarowicz MK (ed.). 2006; 27: 207-212.
4. Hayes DF. Clinical importance of prognosis factors. Moving from scienting to clinical useful. In: Principles of Molecular Oncology. Bronchud MH et al. (eds). 2004; 51-72.
5. Olszewski WT. Patomorfologiczne czynniki prognostyczne w raku piersi. Nowa Med 2002; 6: 119.
6. Olszewski WT. Patomorfologiczne czynniki prognostyczne. W: Onkologia kliniczna. Krzakowski M (red.). Warszawa 2001; 258-273.
7. Pierzchała RP, Paszcz-Walczak G, Jeziorski A. Nowe czynniki rokownicze w raku piersi-przegla{ogonek}d piśmiennictwa. Współcz Onkol 2004; 8, 9: 429-434.
8. Tayassoli FA, Deville P. Tumors of the Breast and Female Genital Organs. WHO Classification of Tumors, 2003.
9. Allred DC, Harvey JM, Berardo M, Clark BM. Prognostic and predictive factors in breast cancer by immunohistochemichal analysis. Mod Pathol 1998; 11: 155-168
10. Domagała W. Klasyczne i nowe czynniki prognostyczne w raku sutka u kobiet. Nowotwory 1996; 47: 23.
11. Hammond MEH. College of American Pathologists Conference prognostic factors which, how and so what? Arch Path Lab Med 2000; 124: 958.
12. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
13. Fitzgibbons PL. Breast Cancer In Prognostic Factors in Cancer. Gospodarowicz MK (ed.). New York 2001; 153: 465-466.
14. Buzdar A. Adjuvant Chemotherapy for High-Risk Operable Breast Cancer 2007; JCO 25: 1642-1644.
15. Olszewski WP, Mrozkowiak A, Suszyło K, et al. Oznaczanie statusu genów TOPA 2 i HER 2 w raku piersi metoda{ogonek} fluorescencyjnej hybrydyzacji in situ (FISH). Zakład Patologii Centrum Onkologii w Warszawie. Klinika Nowotworów Piersi i chirurgii Rekonstrukcyjnej Centrum Onkologii w Warszawie. Program Badań-zadanie wieloletnie 2006.
16. Ravdin PM. Prognostic factors in breast cancer. In: Textbook of breast cancer. A clinical guide to therapy. Bonadonna G, Hortobagyi GN, Giani M, Dunitz M (eds). London 1997; 35-63
17. Bakshi RP, Galande S, Muniyappa K. Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase (review). Crit Rev Biochem Mol Biol 2001; 36: 1-37.
18. Bar JK, Grelewski P, Gabryś M. Expression of topoisomerase I and II alpha in ovarian neoplasms. Pol J Pathol 2007; 2: 110.
19. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα. Am J Pathol 1995; 146: 1302-1308.
20. Costa MJ, Hansen CL, Holden JA, Guinee DJ. Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol 2000; 19: 248-257.
21. Goodsell DS. Topoizomerazy. Biotechnolog. Pl, Serwis biotechnologiczny Copyright 2006.
22. Hellemans P. Immunohistochemical study of topoisomerase II alpha expression in primary ductal carcinoma of the breast. JCO 1995; 48: 147-150.
23. Murphy DS, McHardy P, Coutts J, et al. Interphase cytogenetic analysis of ERBB2 and TOP2A co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 1996; 64: 18-26.
24. Steward C, Ratain M. Pharmacology of cancer chemotherapy. Topoisomerase interactive agents. In: Principles and Practice in Oncology. De Vita, et al. (eds). Philadelphia 2001; 415-418.
25. Binaschi M, Capranico G, Dal Bo L, et al. Relationship between lethal effects and topoisomerase II mediated double-stranded DNA breaks produced by anthracyclines with different sequence specifity. Mol Pharmacol 1997; 51: 1053-1059.
26. Binaschi M, Farinosi R, Borgetto ME, et al. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II poisoning anthracyclines. Cancer Res 2000; 60: 3770.
27. Siedlecki JA. Biologia molekularna nowotworów. W: Onkologia kliniczna. Krzakowski M (red.). Borgis, Warszawa 2006; 61.
28. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005; 23: 5386.
29. Bhargava R, Lal P, Chen B, et al. HER 2/neu and Topoisomerase II alpha Gene Amplification and Protein Expression in Invasive Breast Carcinomas, Am J Clin Pathol 2005; 123: 889-895.
30. Durbecq V, Leo A, Cardoso F, et al. Comparison of topoisomerase II alpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003; 77: 199-204.
31. Kreipe H, Heidebrecht HJ, Hansen S, et al. A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 1993; 142: 3-9.
32. Olszewski WP, Mrozkowiak A, Kosińska-Bauer, et al. Coamplification of HER2 and topa 2 alpha genes in selected cases of breast carcinoma. Pol J Pathol 2007; 2: 130.
33. Olszewski WT. Diagnostyka nowotworów-patomorfologiczne nowe techniki specjalne. Nowa Medycyna-Onkologia V 2000; 10.
34. Płuciennik E, Byczewska M, Seta K, et al. Determination of gene expression in breast cancer. Pol J Pathol 2007; 2: 133.
35. Isola J, Tanner M, Forsyth A, et alInterlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004; 10: 4793-4798.
36. Järvinen TA, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996; 148: 2073-2082.
37. Lynch BJ, Guinee DG, Holden JA. Human DNA topoisomerase II alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997; 28: 1180-1188.
38. Mueller R. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples, genes, chromosomes, Cancer 2004, 39: 288-297.
39. Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase II alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000; 68: 137-143.
40. Veronesi U. Breast cancer. Lancet 2005; 365: 1727-1741.
41. Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER 2 status in breast cancer. Br J Cancer 2003; 88: 1587-1591.
42. Arpino G, Ciocca DR, Weiss H, et al. Predictive value of apoptosis, proliferation HER 2 and topoisomerase II alpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 2005; 92: 69-75.
43. Tanner M, Järvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-5348.
44. Harris LN, Yang L, Liotcheva V, et al. Induction of topoisomerase II activity after ErbB-2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7: 1497-1504.
45. Durbeq V, Leo A, Cardoso F, et al. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 2004; 25: 1473-1479.
46. Olszewski WT, Krzakowski M, et al. Rekomendacje Polskiej Grupy Badawczej ds. HER 2. Nowotwory 2004, 54: 500-505.
47. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki 67, HER 2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205-11.
48. Järvinen TA, Tanner M, Bärlund M, et al. Amplification and deletion of topoisomerase II alpha associate with Erb-2 amplification and affect sensitivity to topoisomerase II alpha inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 3: 839-846.
49. Cardoso F, Durbecq V, Larsimont D, et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24: 201-209.
50. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
51. Di Leo A, Larsimont D, Gancberg D, et al. HER 2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 2001; 12: 1081-1089.
52. Järvinen TA, Liu ET. HER-2/neu and topoisomerase IIalpha-simultaneous drug targets in cancer. Breast Cancer Res Treat 2003; 78: 299-311.
53. Järvinen TA, Tanner M, Bärlund M, et al. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26: 142-150.
54. Krzakowski M. Podstawy kliniczne hormonoterapii nowotworów. W: Onkologia kliniczna. Krzakowski M (red.). Borgis, Warszawa 2006; 193.
55. Jacobson KK, Morrison LE, Henderson BT, et al. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 2004; 40: 19-31.
56. Rudolph P, Olsson H, Bonatz G, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas prognostic implications. J Pathol 1999; 187: 207-216.
57. Simpson JF, Gray R, Dressler LG, et al. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000; 10: 2059-2069.
58. Leonard D. Molecular Pathology in Clinical Practice. Springer Verlag 2007.
59. Loeb L, Loeb K, Anderson JP. Multiple mutations in cancer. Proc Natl Sci U S A 2003; 100: 776.
60. Villman K, Stahl E, Liljegren G, et al. Topoisomerase II alpha expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 2002; 15: 486-491.
61. Isaacs RJ, Davies SJ, Sandri MI, et al. Physiological regulation of eukaryotic topoisomerase II. Biochem Biophys Acta 1998; 1400: 121-137.
62. Szuławska A, Czyż M. Molekularne mechanizmy działania antracyklin. Poste{ogonek}py Higieny Dośw 2006; 60: 78-100.
63. Baak JP, Path FR, Hermsen MA, et al. Genomics and proteomics in cancer. Eur J Cancer 2003; 39: 1199-1215.
64. Houlbrook S, Addison CM, Davies SL, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995; 72: 1454-1461.
65. Olsen KE, Knudsen H, Rasmussen BB, et al.; Danish Breast Cancer Cooperative Group. Amplification of HER 2 and TOP 2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004; 43: 35-42.
66. Olszewski WP. HER2 status in breast carcinoma-practical information for physicians. Nowa Medycyna-Badania nad rakiem 2005; 1.
67. Stacey DW, Hitomi M, Chen G. Influence of cell cycle and oncogene activity upon topoisomerase II alpha expression and drug toxicity. Mol Cell Biol 2000; 20: 9127-9137.
68. Goswami PC, Sheren J, Albee LD, et al. Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3'-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation. J. Biol Chem 2000; 275: 384-392.
69. Mrozkowiak A, Olszewski WP, Suszyło K, et al. The Usefulness of fluorescent in situ hybridization (FISH) in the algorithm of diagnosis management in Breast cancer. Pol J Pathol 2007; 2: 128.
70. Wang JC. Cellular roles of DNA topoisomerases a molecular perspective Nat Rev Mol Cell Biol 2002; 3: 430-440.